[Abstract] Objective: This study aims to investigate the application of clinical pathway for patients with hysteromyoma by conducted a systematic review and meta-analysis. Methods: WanFang, CNKI, VIP and CBM databases were searched extensively to identify relevant clinical controlled trials. Data were analyzed by RevMan 5.1.6 and STATA 10.0 softwares. Results were described as standardized mean difference (SMD) or odds ratio (OR) with 95% confidence intervals (CI). Results: Finally, a total of 11 clinical controlled trials involving 998 hysteromyoma patients were included in this systematic review, including 498 patients in clinical pathway group and 500 patients in control group. Meta-analysis showed the case group got a shorter average length of stay, less hospital cost and higher satisfaction than the control group(SMD= -1.60, 95%CI= -1.75~-1.45, P＜0.00001; SMD= -1.17，95%CI= -1.40~-0.95, P＜0.00001; OR=7.88, 95%CI=4.09~15.16, P＜0.00001, respectively), there was statistically significant differences between this two group. Conclusion: The present data suggests that clinical pathway may reduce the cost of care, cut the average length of stay significantly and have good improvement of clinical effect for patients with hysteromyoma. Further well-designed randomized controlled trials are needed to confirm or adjust current conclusions.